
Two dead, another infected, as rare brain disease reported in one Oregon county
Two people are believed to have died of a rare, incurable brain disease within months of each other in a single Oregon county.
Health officials said in a recent statement that three cases of Creutzfeldt-Jakob Disease have been found in Hood River County, 70 miles east of Portland, in the past eight months.
Two of the cases resulted in death, according to The Oregonian. One of the cases was confirmed by autopsy, while two are presumptive diagnoses, the newspaper said.
It is not known whether the cases are linked, the Hood River County Health Department said Friday.
Health officials said that while the risk to the public remains 'extremely low' they are monitoring the situation closely.
'We're trying to look at any common risk factors that might link these cases,' Hood River County Health Department director Trish Elliot told the outlet. 'But it's pretty hard in some cases to come up with what the real cause is.'
Elliot said the only way to confirm the disease is to test the brain and spinal fluid after death. The results of those tests can take months to establish.
The Independent has contacted the Hood River County Health Department for more information.
Creutzfeldt-Jakob causes rapidly intensifying symptoms that present movement disorders and behavioral changes, similar to Alzheimer's.
The rare and deadly disorder is caused by infectious proteins called prions, which can cause small holes in the brain that resemble sponges under a microscope.
There is currently no treatment or cure. Deaths typically occur 12 months after infection.
According to the Centers for Disease Control and Prevention, approximately 500 to 600 new cases occur in the U.S. each year. Most cases are believed to be hereditary, linked to a genetic mutation passed on from a parent.
The disease cannot be spread from person to person except through organ or tissue transplants or other exposure to infected brain or nervous tissue.
In rare cases, Variant Creutzfeldt-Jakob Disease is linked to eating infected beef from cows with a related disease.
Elliott said the three Hood River cases are not believed to be related to infected cattle.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Leader Live
2 hours ago
- Leader Live
Covid booster warning as Covid NB.1.8.1 cases on the rise
The message comes after health experts also warned of a new COVID-19 variant, with cases of the strain are on the rise around the world. Covid NB.1.8.1 is a variation of the XDV.1.5.1 strain and was first detected back in January 2025. Ifti Khan, superintendent pharmacist at Well Pharmacy, urged those eligible to book as soon as possible and get the booster while it is still available. He said: 'Covid will most likely rise coming into the end of spring and into summer as people mix with friends and family more often. 'We know from previous boosters that they are effective in making sure that patients' symptoms are not as severe as they might have been without so I would urge patients to pop into their local Well Pharmacy store and get their jab. 'Patients have just over two weeks as the spring booster programme ends on June 17 so it would be my hope that those who can get a jab, opt to do so before enjoying socialising during summer.' Mr Khan warned that at this time of year, some people may believe they have hay fever as early symptoms of Covid include a runny or blocked nose or a sore throat. Covid tests can be obtained at any Well Pharmacy. The WHO has placed the Covid NB.1.8.1 "under monitoring" due to the rise in cases worldwide. It is one of six COVID-19 variants currently being monitored. The new 'Strategic and operational plan for coronavirus disease threat management: at a glance' sets out the global framework for supporting Member States in the sustained, integrated, evidence-based management of coronavirus disease threats, including #COVID19, MERS, and… However, the WHO stated that the risk posed by the new variant was "low," and that approved COVID-19 vaccines are expected to be effective against it. The world health experts, in a recent risk evaluation, said: "Despite a concurrent increase in cases and hospitalisations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation. The WHO added: "The available evidence on NB.1.8.1 does not suggest additional public health risks relative to the other currently circulating Omicron descendent lineages." COVID NB.1.8.1 has already been detected in 22 countries. These include the likes of Australia, China, Hong Kong, Thailand and the US, according to The Independent. The coming COVID-19 Winter Surge in Australia will show the world where we are actually headed is happening in South-Eats Asia and East Asia are just the 'preludes'...watch how NB.1.8.1 spawns are evolving including PQ.1, PQ.2 and even sub-lineages like PE.1. Cases of the NB.1.8.1 variant have also been confirmed in Northern Ireland, Wales, and "popular British tourist hotspots", the news outlet added.

Rhyl Journal
3 hours ago
- Rhyl Journal
Covid booster warning as Covid NB.1.8.1 cases on the rise
The message comes after health experts also warned of a new COVID-19 variant, with cases of the strain are on the rise around the world. Covid NB.1.8.1 is a variation of the XDV.1.5.1 strain and was first detected back in January 2025. Ifti Khan, superintendent pharmacist at Well Pharmacy, urged those eligible to book as soon as possible and get the booster while it is still available. He said: 'Covid will most likely rise coming into the end of spring and into summer as people mix with friends and family more often. 'We know from previous boosters that they are effective in making sure that patients' symptoms are not as severe as they might have been without so I would urge patients to pop into their local Well Pharmacy store and get their jab. 'Patients have just over two weeks as the spring booster programme ends on June 17 so it would be my hope that those who can get a jab, opt to do so before enjoying socialising during summer.' Mr Khan warned that at this time of year, some people may believe they have hay fever as early symptoms of Covid include a runny or blocked nose or a sore throat. Covid tests can be obtained at any Well Pharmacy. The WHO has placed the Covid NB.1.8.1 "under monitoring" due to the rise in cases worldwide. It is one of six COVID-19 variants currently being monitored. The new 'Strategic and operational plan for coronavirus disease threat management: at a glance' sets out the global framework for supporting Member States in the sustained, integrated, evidence-based management of coronavirus disease threats, including #COVID19, MERS, and… However, the WHO stated that the risk posed by the new variant was "low," and that approved COVID-19 vaccines are expected to be effective against it. The world health experts, in a recent risk evaluation, said: "Despite a concurrent increase in cases and hospitalisations in some countries where NB.1.8.1 is widespread, current data do not indicate that this variant leads to more severe illness than other variants in circulation. The WHO added: "The available evidence on NB.1.8.1 does not suggest additional public health risks relative to the other currently circulating Omicron descendent lineages." COVID NB.1.8.1 has already been detected in 22 countries. These include the likes of Australia, China, Hong Kong, Thailand and the US, according to The Independent. The coming COVID-19 Winter Surge in Australia will show the world where we are actually headed is happening in South-Eats Asia and East Asia are just the 'preludes'...watch how NB.1.8.1 spawns are evolving including PQ.1, PQ.2 and even sub-lineages like PE.1. Cases of the NB.1.8.1 variant have also been confirmed in Northern Ireland, Wales, and "popular British tourist hotspots", the news outlet added.


North Wales Chronicle
3 hours ago
- North Wales Chronicle
Alzheimer's blood test ‘can accurately pick up early symptoms'
Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'